But right now, is one recent disturbing trend bad news for Lilly in this key growth market? Let's find out. So, first, a bit of background on these pharma companies' portfolios. Novo sells semaglutide ...

When Laura Patnaude stepped into her wedding gown for her first fitting last month, she asked her seamstress, “How much ...

For more than a decade, Zeds Dead have turned Denver’s Fourth of July weekend into a pilgrimage for bass music fans. What ...

Consumers should be more circumspect when considering these telehealth sites. They might provide an easier or cheaper avenue ...

The popular obesity drugs are being cavalierly prescribed. It should be yet another wake-up call for regulators. Virtual clinics are popular with patients who have become frustrated by the often ...

GLP-1 medications have transformed the way doctors treat obesity in adults — but as demand grows, a new question is emerging: ...

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set as demand for obesity therapeutics keeps ...

And the conversation has moved well past "does it work." People are now asking a bigger question: if a huge chunk of the ...

Contrave and Zepbound are two U.S. Food and Drug Administration (FDA)-approved medications for weight loss when combined with diet and exercise. But each medication works in different ways in the body ...

The hospital said it would expect to save $19 million dollars each year, but staff are skeptical of the long-term costs.

For decades, it's been against the law for Medicare to pay for weight-loss medication. But that changed on July 1, with the ...

Older Americans previously could only access GLP-1 coverage for diabetes or cardiovascular disease through Medicare. See if you qualify now. Some Medicare patients will soon have access to GLP-1 drugs ...